AstraZeneca Presents Reports P-III Trial (ADAURA) Results of Tagrisso (osimertinib) for Early-Stage EGFR-Mutated Lung Cancer at ASCO 2023
Shots:
- The P-III trial evaluating Tagrisso (80mg, qd) vs PBO in 682 patients with stage IB, II, IIIA EGFRm NSCLC at 200+ centers across 20+ countries, incl. the US, EU, South America, Asia & the Middle East
- The results showed an improvement in OS, a 51% reduction in risk of death in the primary analysis population (Stages II-IIIA) (21% data maturity) & in the overall trial population (Stages IB-IIIA) (18% data maturity)
- In both populations, patients were alive (85% vs 73% at 5yrs.) & (88% vs 78%); m-OS (not reached) in either population or treatment group. The safety & tolerability were consistent with the established profile and previous analyses with no new safety concerns, grade 3 or higher from all causes (23% vs 14%)
Ref: Businesswire | Image: Astrazenneca
Related News:- AstraZeneca Reports P-III Trial (FLAURA2) Results of Tagrisso (osimertinib) for the Treatment of EGFR-Mutated Advanced Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
